CorMedix Inc. (NASDAQ: CRMD) saw its stock soar 7.42% in pre-market trading on Tuesday following the release of its stellar first-quarter 2025 financial results. The biopharmaceutical company significantly outperformed analyst expectations, driving investor enthusiasm.
CorMedix reported earnings per share (EPS) of $0.30 for Q1 2025, handily beating the consensus estimate of $0.24 by 25%. This marks a remarkable turnaround from the $0.25 loss per share reported in the same quarter last year. The company's revenue also impressed, coming in at $39.08 million, surpassing analyst projections of $36 million by 8.55%. Net income for the quarter stood at a robust $20.6 million, significantly exceeding the estimated $16.4 million.
Investors were further encouraged by CorMedix's strong financial position, with the company reporting cash and investments of $77.5 million at the end of the quarter. Looking ahead, CorMedix provided an optimistic outlook, stating that it expects to reach the high end of its first-half 2025 sales guidance range of $62 million to $70 million. This combination of strong current performance and positive future prospects likely contributed to the stock's pre-market rally, as investors anticipate continued growth and improved profitability for the company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.